Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. have secured United States Food and Drug Administration approval for SIMTRIYO, or centanafadine, as a once-daily extended-release treatment for attention-deficit hyperactivity disorder in adults and pediatric patients aged six years and older who weigh at least 20 kilograms. The decision establishes SIMTRIYO as the first approved norepinephrine, dopamine and serotonin reuptake inhibitor for ADHD, although commercial availability remains dependent on scheduling by the United States Drug Enforcement Administration and is expected later in 2026.
The approval gives Otsuka a broad age-spanning ADHD label and a differentiated pharmacological mechanism, two attributes that could support a substantial commercial opportunity. It does not, however, create an immediately available medicine or establish superiority over existing stimulant and non-stimulant therapies. The practical value of SIMTRIYO will depend on how its efficacy, tolerability, boxed warnings and controlled-substance requirements are assessed against an already mature treatment market.
That distinction is particularly important because SIMTRIYO is sometimes likely to be viewed primarily through its triple-reuptake mechanism. The FDA label classifies it as a central nervous system stimulant, and the product carries boxed warnings covering suicidal ideation and behaviors in pediatric patients as well as abuse, misuse and addiction. Its novelty therefore lies in how it modulates three neurotransmitter systems, not in avoiding the regulatory and monitoring considerations associated with stimulant treatment.
What exactly has the FDA approved for SIMTRIYO, and where does the label restrict its use?
The approved indication covers adults and pediatric patients aged six years and older who weigh at least 20 kilograms. SIMTRIYO will be supplied as extended-release capsules containing 140 milligrams, 210 milligrams or 280 milligrams of centanafadine and is intended for morning administration once daily, with or without food. The capsules may be swallowed whole or opened, with the entire contents administered in applesauce, yogurt or orange juice, which may provide practical flexibility for some pediatric patients.
Dosing is not uniform across the approved population. Children aged six to 12 receive weight-based dosing, with 140 milligrams used for those weighing 20 kilograms to less than 35 kilograms, 210 milligrams for those weighing 35 kilograms to 50 kilograms, and 280 milligrams for those above 50 kilograms. Adolescents aged 13 to 17 receive 280 milligrams once daily, while adults begin at 210 milligrams and may increase to 280 milligrams according to clinical response and tolerability.
The label also draws firm pediatric boundaries. Use is not recommended below the age of six because younger children experienced a higher incidence of weight loss, while patients weighing less than 20 kilograms were excluded because of limited data and the same weight-related concern. Those limitations matter commercially because they exclude younger and smaller children from the initial addressable population, even though the broader announcement describes an approval extending from childhood through adulthood.
The approved dosage further reflects an important finding from the pediatric programme. Lower experimental doses failed to demonstrate statistically significant superiority over placebo in the six-week child and adolescent studies. Only the higher exposure corresponding to the approved weight-based paediatric regimen, and the approved 280-milligram adolescent regimen, established efficacy on the primary symptom scale.
How convincing is the four-trial Phase 3 evidence supporting SIMTRIYO’s broad ADHD label?
The regulatory package included four randomized, double-blind, placebo-controlled Phase 3 trials, comprising one study in children aged six to 12, one in adolescents aged 13 to 17 and two in adults. This is a more substantial evidence base than an approval resting on a single pivotal study, although the controlled treatment periods were limited to six weeks and do not answer every question concerning long-term comparative effectiveness.
In the child study, patients receiving the approved high-exposure, weight-adjusted regimen experienced a least-squares mean reduction of 16.3 points on the ADHD Rating Scale-5, compared with a 10.8-point reduction for placebo. The placebo-subtracted difference was 5.6 points, with a 95 percent confidence interval ranging from 2.33 to 8.78 points in favour of centanafadine. A total of 480 patients aged six to 12 were randomized, although efficacy results used for the label excluded younger participants and focused on those within the approved age and weight limits.
Among adolescents, the approved 280-milligram dose produced an 18.5-point mean reduction on the ADHD Rating Scale-5 at week six, compared with a 14.2-point reduction for placebo. The placebo-adjusted difference was 4.4 points, with the confidence interval excluding no effect. The lower 140-milligram dose did not achieve a statistically significant difference and was therefore not approved for this population.
The two adult studies randomized a combined 906 participants and used the Adult ADHD Investigator Symptom Rating Scale as their primary efficacy measure. Across the two trials, placebo-adjusted differences ranged from 2.7 to 4.4 points, depending on study and dose. Both studies also reported statistically significant improvements on the Clinical Global Impression-Severity scale.
The adult programme requires a small but meaningful regulatory nuance. Those studies evaluated another sustained-release formulation of centanafadine rather than the final once-daily SIMTRIYO formulation. The prescribing information states that no difference in effectiveness is expected between the studied low and high doses and the approved 210-milligram and 280-milligram SIMTRIYO doses, respectively. That bridging was accepted by the FDA, but clinicians and market observers should understand how the adult evidence was connected to the commercial formulation.
These data establish placebo-controlled efficacy across the approved populations. They do not establish that SIMTRIYO is more effective than amphetamine products, methylphenidate products, atomoxetine, viloxazine or other available ADHD therapies. Differences in study populations, dosing, endpoints and trial duration also make indirect comparisons unreliable without head-to-head evidence.
Why could SIMTRIYO’s triple-reuptake mechanism matter without proving clinical superiority?
Centanafadine inhibits the reuptake of norepinephrine, dopamine and serotonin, increasing the availability of those neurotransmitters in pathways associated with attention and behavioural regulation. Otsuka describes SIMTRIYO as the first and only approved NDSRI for ADHD, creating a pharmacological category that is distinct from conventional amphetamine and methylphenidate products as well as established non-stimulant options.
Mechanistic differentiation can be commercially useful in a heterogeneous disorder. ADHD treatment commonly involves individual experimentation with dose, formulation and drug class because response and tolerability vary considerably. A medicine with a new mechanism may therefore gain relevance among patients who experience insufficient benefit, undesirable adverse effects or practical difficulties with existing therapies.
However, a first-in-class designation describes novelty rather than the magnitude of patient benefit. The pivotal trials were placebo-controlled, and the label provides no evidence that triple-reuptake inhibition produces better symptom control, improved functional outcomes or a more favourable risk-benefit profile than established products. Otsuka will ultimately need prescribing experience, real-world persistence data and ideally comparative studies to show where SIMTRIYO fits within treatment sequencing.
The product’s once-daily formulation may become just as commercially relevant as its mechanism. Once-daily morning administration can simplify treatment routines compared with products requiring afternoon dosing or more complicated titration. Yet many competing ADHD medicines already offer extended-release or once-daily administration, meaning convenience alone is unlikely to create decisive differentiation.
How will SIMTRIYO’s boxed warnings influence pediatric prescribing and long-term monitoring?
The most consequential safety issue for the pediatric launch is the boxed warning concerning suicidal ideation and behaviors. The label states that higher rates occurred among SIMTRIYO-treated patients aged six to 12 than among those receiving placebo and requires close monitoring of all pediatric patients for emerging suicidal thoughts, behaviors, clinical deterioration or unusual behavioral changes.
The underlying data require careful, proportionate interpretation. In the six-week study involving children aged six to 12, suicide attempts were reported in two of 304 centanafadine-treated participants, representing 0.7 percent, compared with none of 153 placebo recipients. In the long-term open-label pediatric study, suicidal ideation was reported in five of 620 patients, or 0.8 percent, and led to discontinuation in four patients. The trial data do not support dismissing the signal, but neither should they be used to imply that every reported event was necessarily caused by the medicine.
Common adverse reactions also varied by age. Rash and decreased appetite were the most frequently reported reactions among children aged six to 12, while adolescents commonly experienced decreased appetite, nausea, rash, headache and abdominal pain. Adults most commonly reported headache, decreased appetite, insomnia, nausea, dry mouth and diarrhoea.
Treatment discontinuations provide additional insight into tolerability. Six percent of high-dose SIMTRIYO recipients aged six to 12 discontinued because of adverse reactions, compared with 1 percent receiving placebo, with rash accounting for the most frequent treatment-ending event. Among adolescents, 8 percent receiving 280 milligrams discontinued because of adverse reactions, compared with none receiving placebo. In the adult studies, discontinuation occurred in 6 percent of high-dose patients and 5 percent of low-dose patients, compared with 1 percent of placebo recipients.
Growth and weight monitoring will also be central to pediatric use. During the six-week child study, average weight declined by 0.6 kilograms with SIMTRIYO while increasing by 0.8 kilograms with placebo. Adolescents receiving SIMTRIYO lost an average of 1.2 kilograms, compared with a 0.6-kilogram gain among placebo recipients. The label advises monitoring weight, body mass index and linear growth and considering treatment interruption when expected growth is not maintained.
Why does pending DEA scheduling remain a genuine commercial hurdle after FDA approval?
SIMTRIYO’s FDA approval does not mean pharmacies can immediately begin dispensing the product. The prescribing information identifies centanafadine as a controlled substance whose schedule remains to be determined after review by the United States Drug Enforcement Administration, and Otsuka expects commercial availability only after that process is completed.
The scheduling decision will determine several practical aspects of the launch, including prescribing controls, refill procedures, pharmacy handling and storage expectations. These factors can affect convenience for clinicians and patients, particularly in a market where administrative friction already varies considerably between stimulant and non-stimulant therapies.
The label’s second boxed warning explicitly states that SIMTRIYO has the potential for abuse and misuse and that misuse of central nervous system stimulants can result in substance use disorder, overdose or death. Two human abuse-potential studies found that centanafadine produced drug-liking responses greater than placebo. The prescribing information therefore concludes that the compound has abuse potential, making it premature to position the product as a low-burden alternative before the DEA completes its assessment.
Otsuka’s immediate commercial milestone is consequently not the approval itself but completion of scheduling followed by product availability. Pricing, payer negotiations, formulary placement and patient-support arrangements will then determine whether the company can convert regulatory novelty into actual prescriptions.
Could the adult anxiety study strengthen SIMTRIYO’s profile beyond the initial ADHD approval?
Otsuka has also reported topline Phase 3b results from a 315-patient study in adults with ADHD and comorbid generalized anxiety disorder, social anxiety disorder or both. Participants receiving centanafadine experienced an 18.5-point reduction on the Adult ADHD Investigator Symptom Rating Scale at week eight, compared with a 12.6-point reduction for placebo, producing a placebo-adjusted difference of 5.87 points.
The trial also reported a statistically significant difference on the Hamilton Anxiety Rating Scale, although the placebo-adjusted improvement was more modest at 1.92 points. Full findings have not yet been presented at a scientific meeting or published in peer-reviewed form, so the topline disclosure should be treated as supportive evidence rather than a complete basis for assessing the clinical relevance of the anxiety result.
The study does not mean SIMTRIYO is approved to treat anxiety. Its potential commercial value lies in generating evidence about a clinically complex ADHD subgroup that can be difficult to manage. Detailed data on baseline severity, discontinuations, adverse events and consistency across anxiety diagnoses will be needed before the findings can materially alter prescribing perceptions.
What will determine whether SIMTRIYO becomes a growth driver for Otsuka Holdings?
Otsuka enters the launch with an established United States neuroscience commercial presence that includes ABILIFY MAINTENA, ABILIFY ASIMTUFII, REXULTI and NUEDEXTA. That infrastructure should reduce the organisational burden of building prescriber relationships from scratch, even though ADHD involves a broader mix of pediatricians, primary-care physicians and specialists than some of Otsuka’s existing psychiatric franchises.
Centanafadine has also been identified by Otsuka Holdings Co., Ltd. as one of the company’s future pharmaceutical growth drivers. FDA approval removes the largest regulatory uncertainty, but the product must still compete with established brands, inexpensive generics and treatment approaches with decades of prescriber familiarity.
Otsuka Holdings shares closed at ¥11,155 on July 24, rising 2.2 percent and becoming the strongest percentage gainer in the Nikkei 225 during a broadly weaker Japanese session. The stock remained close to the upper end of its reported 52-week range, indicating positive broader sentiment toward the company, although the movement should not automatically be attributed to the SIMTRIYO announcement without clear evidence regarding market timing and investor causation.
SIMTRIYO therefore reaches the market with a genuine regulatory distinction, a broad approved population and evidence from four successful Phase 3 trials. Its first commercial test will be the speed and outcome of DEA scheduling. The more important long-term test will be whether clinicians and payers see sufficient value in its mechanism, symptom improvements and once-daily formulation to accept the monitoring burden, boxed warnings and likely access controls attached to another controlled ADHD stimulant.
